Detalhe da pesquisa
1.
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥â¯60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023.
Euro Surveill
; 29(3)2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38240061
2.
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.
Euro Surveill
; 29(8)2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38390651
3.
Establishing severe acute respiratory infection (SARI) surveillance in a sentinel hospital, Ireland, 2021 to 2022.
Euro Surveill
; 28(23)2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289427
4.
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥â¯20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
Euro Surveill
; 28(47)2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37997666
5.
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥â¯20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
Euro Surveill
; 28(47)2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37997665
6.
Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.
Influenza Other Respir Viruses
; 18(2): e13255, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38403302